1. Home
  2. VRAR vs PMN Comparison

VRAR vs PMN Comparison

Compare VRAR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAR
  • PMN
  • Stock Information
  • Founded
  • VRAR 2016
  • PMN 2004
  • Country
  • VRAR United States
  • PMN Canada
  • Employees
  • VRAR N/A
  • PMN N/A
  • Industry
  • VRAR Retail: Computer Software & Peripheral Equipment
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • VRAR Technology
  • PMN Health Care
  • Exchange
  • VRAR Nasdaq
  • PMN Nasdaq
  • Market Cap
  • VRAR N/A
  • PMN 18.8M
  • IPO Year
  • VRAR 2021
  • PMN N/A
  • Fundamental
  • Price
  • VRAR $1.11
  • PMN $0.58
  • Analyst Decision
  • VRAR Strong Buy
  • PMN Strong Buy
  • Analyst Count
  • VRAR 1
  • PMN 1
  • Target Price
  • VRAR $2.62
  • PMN $6.00
  • AVG Volume (30 Days)
  • VRAR 98.1K
  • PMN 38.8K
  • Earning Date
  • VRAR 05-14-2025
  • PMN 05-13-2025
  • Dividend Yield
  • VRAR N/A
  • PMN N/A
  • EPS Growth
  • VRAR N/A
  • PMN N/A
  • EPS
  • VRAR 0.86
  • PMN 0.11
  • Revenue
  • VRAR $591,251,000.00
  • PMN N/A
  • Revenue This Year
  • VRAR N/A
  • PMN N/A
  • Revenue Next Year
  • VRAR $30.43
  • PMN N/A
  • P/E Ratio
  • VRAR N/A
  • PMN $5.55
  • Revenue Growth
  • VRAR N/A
  • PMN N/A
  • 52 Week Low
  • VRAR $0.50
  • PMN $0.51
  • 52 Week High
  • VRAR $7.00
  • PMN $2.37
  • Technical
  • Relative Strength Index (RSI)
  • VRAR 47.78
  • PMN 42.83
  • Support Level
  • VRAR $1.09
  • PMN $0.51
  • Resistance Level
  • VRAR $1.08
  • PMN $0.65
  • Average True Range (ATR)
  • VRAR 0.08
  • PMN 0.07
  • MACD
  • VRAR 0.02
  • PMN 0.01
  • Stochastic Oscillator
  • VRAR 60.00
  • PMN 40.62

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: